Journal of Affective Disorders
Volume 82, Issue 2 , Pages 285-290 , 15 October 2004

Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder

Received 25 September 2003 ,Revised 14 November 2003 ,Accepted 14 November 2003.

References 

  1. Arseven A, Guralnik JM, O'Brien E, Liu K, McDermot MM. Peripheral arterial disease and depressed mood in older men and women. Vasc. Med. 2001;6:229–234
  2. Berg KA, Clarke WP. Regulation of 5-HT(1A) and 5-HT(1B) receptor systems by phospholipid signaling cascades. Brain Res. Bull. 2001;56:471–477
  3. Berg KA, Maayani S, Clarke WP. 5-Hydroxytryptamine 2C receptor activation inhibits 5-hydrotryptamine 1B-like receptor function via arachidonic acid metabolism. Mol. Pharmacol. 1996;50:1017–1023
  4. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 1998;54:94–104
  5. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive compulsive and panic disorders. Neuropsychopharmacology. 1999;21:91S–98S
  6. Cambj-Sapunar L, Yu M, Harder DR, Roman RJ. Contribution of 5-hydroxytryptamine 1B receptors and 20-hydroxyeicosateraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke. 2003;34:1269–1275
  7. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect. Disord. 1998;48:149–155
  8. Evans KL, Cropper JD, Berg KA, Clarke WP. Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. J. Pharmacol. Exp. Ther. 2001;297:1025–1035
  9. Felder CC, Kanterman RY, Ma AL, Axelrod J. Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc. Natl. Acad. Sci. USA. 1990;87:2187–2191
  10. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol. Psychiatry. 2000;47:8–21
  11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  12. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect. Disord. 2002;69:15–29
  13. Hibbeln JR, Palmer JW, Davis JM. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness?. Biol. Psychiatry. 1989;25:945–961
  14. Horrobin DF. Schizophrenia: a biochemical disorder. Biomedicine. 1980;32:54–55
  15. Horrobin DF, Jenkins K, Bennett CN, Christie WW. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukotrienes Essent. Fatty Acids. 2002;66:83–90
  16. Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry. 1997;41:507–513
  17. Ingram SL, Amara SG. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the human dopamine transporter. J. Neurosci. 2000;20:550–557
  18. Kanagy NL, Mecca TE, Webb RC. Arachidonate metabolites and serotonin contraction of femoral arteries from DOCA-salt hypertensive rats. Blood Press. 1996;5:113–120
  19. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 2003;304:229–237
  20. Leonard BE. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2001;25:767–780
  21. Lieb J, Karmalie R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukotrienes Med. 1983;10:361–367
  22. Lorenzen A, Stannek C, Burmeister A, Kalvinsh I, Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem. Pharmacol. 2002;64:645–648
  23. Morrow JD, Parsons WG, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following administration of nicotinic acid. Prostaglandins. 1989;38:263–274
  24. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 1992;98:812–815
  25. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry. 2002;159:477–479
  26. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry. 2002;59:913–919
  27. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int. J. Clin. Pract. 2001;55:560–563
  28. Puri BK, Hirsch SR, Easton T, Richardson AJ. A volumetric biochemical niacin flush-based index that non-invasively detects fatty acid deficiency in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26:49–52
  29. Qu Y, Chang L, Klaff J, Balbo A, Rapaport SI. Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agnonist (+/−) 2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology. 2003;28:244–252
  30. Richard M, Vignon E, Peschar MJ, Broquet P, Carret JP, Louisot P. Serotonin-stimulated phospholipase A2 and collagenase activation in chondrocytes from human osteoarthritic cartilage. FEBS Lett. 1991;278:38–40
  31. Ross, B.M., Hughes, B., Turenne, S., Kennedy, J., Seeman, M.V., Warsh, J.J. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. European Neuropsychopharmacol. (in press).
  32. Rybakowski J, Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry. 1991;29:834–836
  33. Shah SH, Vankar GK, Peet M, Ramchand CN. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 2000;43:163–164
  34. Stout BD, Clarke WP, Berg KA. Rapid desensitization of the serotonin receptor system: effector pathway and agonist dependence. J. Pharmacol. Exp. Ther. 2002;302:957–962
  35. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 2003;78:40–46
  36. Tournois C, Mutel V, Manivet P, Launay JM, Kellermann O. Cross-talk between 5-hydrotryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism. J. Biol. Chem. 1998;273:17498–17503
  37. Turenne SD, Seeman M, Ross BM. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophr. Res. 2001;50:191–197
  38. Ward PE, Sutherland J, Glen EMT, Glen AIM. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 1998;29:269–274

PII: S0165-0327(03)00311-2

doi: 10.1016/j.jad.2003.11.005

Journal of Affective Disorders
Volume 82, Issue 2 , Pages 285-290 , 15 October 2004

Article Tools

* Image Usage & Resolution